Carisma Therapeutics (NASDAQ:CARM – Get Rating) and Synaptogenix (NASDAQ:SNPX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Valuation & Earnings This table compares Carisma Therapeutics and Synaptogenix’s […]
/PRNewswire/ Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and.
Carisma Therapeutics (NASDAQ:CARM – Get Rating) will be posting its quarterly earnings results on Friday, May 12th. Carisma Therapeutics Stock Up 2.7 % Shares of CARM stock traded up $0.16 on Thursday, hitting $6.02. 84,394 shares of the stock were exchanged, compared to its average volume of 117,782. The company has a market capitalization of […]
PHILADELPHIA, May 8, 2023 /PRNewswire/ Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced. | May 8, 2023